Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Periplakin as a Potential Biomarker for Urothelial Carcinoma of the Urinary Bladder

  • Matsumoto, Kazumasa (Department of Urology, School of Medicine, Kitasato University) ;
  • Ikeda, Masaomi (Department of Urology, School of Medicine, Kitasato University) ;
  • Matsumoto, Toshihide (Department of Pathology, School of Medicine, Kitasato University) ;
  • Nagashio, Ryo (Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University) ;
  • Nishimori, Takanori (Department of Frontier Surgery, Graduate School of Medicine, Chiba University) ;
  • Tomonaga, Takeshi (National Institute of Biomedical Innovation, Laboratory of Proteome Research) ;
  • Nomura, Fumio (Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University) ;
  • Sato, Yuichi (Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University) ;
  • Kitasato, Hidero (Department of Microbiology, School of Allied Health Sciences, Kitasato University) ;
  • Iwamura, Masatsugu (Department of Urology, School of Medicine, Kitasato University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

The objectives of this study were to examine serum periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum periplakin was performed in 50 patients and 30 normal controls with anti-periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P = 0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum periplakin level may play a role as a non-invasive diagnostic modality to aid urine cytology and cystoscopy.

Keywords

References

  1. Chao Y, Shih YL, Chiu JH, et al (1998). Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res, 58, 985-90.
  2. Choi YK, Woo SM, Cho SG, et al (2013). Brain-metastatic triple-negative breast cancer cells regain growth ability by altering gene expression patterns. Cancer Genomics Proteomics, 10, 265-75.
  3. Clark AS, West K, Streicher S, Dennis PA (2002). Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther, 1, 707-17.
  4. Dobashi Y, Shoji M, Jiang SX, et al (1998). Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol, 153, 963-72. https://doi.org/10.1016/S0002-9440(10)65638-6
  5. Gagnon V, Mathieu I, Sexton E, et al (2004). AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol, 94, 785-95. https://doi.org/10.1016/j.ygyno.2004.06.023
  6. Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-403. https://doi.org/10.7314/APJCP.2014.15.6.2395
  7. Hatakeyama H, Kondo T, Fujii K, et al (2006). Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics, 6, 6300-16. https://doi.org/10.1002/pmic.200600488
  8. Ikeda M, Matsumoto K, Nishi M, et al (2014). Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. Asian Pac J Cancer Prev, 15, 6519-24. https://doi.org/10.7314/APJCP.2014.15.16.6519
  9. Ikeda M, Matsumoto K, Tabata K, et al (2011). Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J Clin Oncol, 41, 1214-20. https://doi.org/10.1093/jjco/hyr131
  10. Jefferson JJ, Leung CL, Liem RK (2004). Plakins: goliaths that link cell junctions and the cytoskeleton. Nat Rev Mol Cell Biol, 5, 542-53. https://doi.org/10.1038/nrm1425
  11. Matsumoto K, Ikeda M, Hirayama T, et al (2014). Clinical value of dividing false positive urine cytology findings into three categories: atypical, indeterminate, and suspicious of malignancy. Asian Pac J Cancer Prev, 15, 2251-5. https://doi.org/10.7314/APJCP.2014.15.5.2251
  12. Matsumoto K, Ikeda M, Sato Y, et al (2014). Loss of periplakin expression is associated with pathological stage and cancerspecific survival in patients with urothelial carcinoma of the urinary bladder. Biomed Res, 35, 201-6. https://doi.org/10.2220/biomedres.35.201
  13. Minami S, Nagashio R, Ueda J, et al (2014). Detection of tumor-associated antigens in culture supernatants using autoantibodies in sera from patients with bladder cancer. Biomed Res, 35, 25-35. https://doi.org/10.2220/biomedres.35.25
  14. Mrena J, Wiksten JP, Kokkola A, et al (2006). Prognostic significance of cyclin A in gastric cancer. Int J Cancer, 119, 1897-901. https://doi.org/10.1002/ijc.21944
  15. Nagata Y, Karashima T, Watt FM, et al (2001). Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol, 116, 556-63. https://doi.org/10.1046/j.1523-1747.2001.01263.x
  16. Nishimori T, Tomonaga T, Matsushita K, et al (2006). Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics, 6, 1011-8. https://doi.org/10.1002/pmic.200500262
  17. Park GT, Quan G, Lee JB (2006). Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. Br J Dermatol, 155, 337-43. https://doi.org/10.1111/j.1365-2133.2006.07323.x
  18. Shelley MD, Mason MD, Kynaston H (2010). Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev, 36, 195-205. https://doi.org/10.1016/j.ctrv.2009.12.005
  19. Sonnenberg A, Liem RK (2007). Plakins in development and disease. Exp Cell Res, 313, 2189-203. https://doi.org/10.1016/j.yexcr.2007.03.039
  20. Sun CH, Chang YH, Pan CC (2011). Activation of the PI3K/ Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology, 58, 1054-63. https://doi.org/10.1111/j.1365-2559.2011.03856.x
  21. Suzuki A, Horiuchi A, Ashida T, et al (2010). Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via upregulation of an Akt-binding protein, periplakin. J Cell Mol Med, 14, 2305-17. https://doi.org/10.1111/j.1582-4934.2009.00839.x
  22. Taille C, Grootenboer-Mignot S, Boursier C, et al (2011). Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 183, 759-66. https://doi.org/10.1164/rccm.201001-0076OC
  23. Toma MI, Friedrich MG, Hautmann SH, et al (2004). Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol, 22, 145-9.
  24. Tonoike Y, Matsushita K, Tomonaga T, et al (2011). Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells. BMC Cell Biol, 12, 41. https://doi.org/10.1186/1471-2121-12-41
  25. Tsumura H, Matsumoto K, Matsumoto T, et al (2014). Increased expression of serum uroplakin III is associated with the detection and pathological features of aggressive bladder cancer. Eur Urol Suppl, 13, 48.
  26. van den Heuvel AP, de Vries-Smits AM, van Weeren PC, et al (2002). Binding of protein kinase B to the plakin family member periplakin. J Cell Sci, 115, 3957-66. https://doi.org/10.1242/jcs.00069
  27. Yang X, Fraser M, Moll UM, et al (2006). Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res, 66, 3126-36. https://doi.org/10.1158/0008-5472.CAN-05-0425

Cited by

  1. Laparoscopic Retroperitoneal Nephroureterectomy is a Safe and Adherent Modality for Obese Patients with Upper Urinary Tract Urothelial Carcinoma vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3223
  2. An epigenome-wide association analysis of cardiac autonomic responses among a population of welders vol.12, pp.2, 2017, https://doi.org/10.1080/15592294.2016.1270486